Filtered By:
Specialty: Cancer & Oncology
Condition: Thrombosis
Education: Study

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 58 results found since Jan 2013.

Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke
Cell Mol Life Sci. 2022 Apr 13;79(5):240. doi: 10.1007/s00018-022-04257-7.ABSTRACTIschemic stroke is a leading cause of death and disability worldwide. Increasing evidence indicates that ischemic stroke is a thromboinflammatory disease in which the contact-kinin pathway has a central role by activating pro-coagulant and pro-inflammatory processes. The blocking of distinct members of the contact-kinin pathway is a promising strategy to control ischemic stroke. Here, a plasma kallikrein and active FXII (FXIIa) inhibitor (sylvestin, contained 43 amino acids, with a molecular weight of 4790.4 Da) was first identified from fore...
Source: Cancer Control - April 13, 2022 Category: Cancer & Oncology Authors: Zhiye Zhang Chuanbin Shen Mingqian Fang Yajun Han Chengbo Long Weihui Liu Min Yang Ming Liu Dengdeng Zhang Qiqi Cao Xue Chen Yaqun Fang Qiumin Lu Zongliu Hou Yaxiong Li Zhenze Liu Xi Lei Heyu Ni Ren Lai Source Type: research

Stroke with intracranial stenosis is associated with increased platelet activation in sickle cell anemia
ConclusionStroke with intracranial stenosis is associated with increased platelet activation in sickle cell anemia, and further investigation is needed on the role of anti‐platelet agents in this high‐risk population. Pediatr Blood Cancer © 2013 Wiley Periodicals, Inc.
Source: Pediatric Blood and Cancer - March 18, 2013 Category: Cancer & Oncology Authors: Suvankar Majumdar, Samantha Webb, Erin Norcross, Venkat Mannam, Naveed Ahmad, Seth Lirette, Rathi Iyer Tags: Research Article Source Type: research

Distance to Thrombus in acute middle cerebral artery stroke predicts basal ganglia infarction after mechanical thrombectomy.
CONCLUSION: In MCA stroke, the exact site of the occlusion as measured by DT independently predicts the involvement of LSAs and subsequent striatocapsular infarction with high sensitivity and specificity. PMID: 27845905 [PubMed - as supplied by publisher]
Source: Oncotarget - November 16, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Repurposing antimycotic ciclopirox olamine as a promising anti-ischemic stroke agent
Publication date: Available online 14 August 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Hongxuan Feng, Linghao Hu, Hongwen Zhu, Lingxue Tao, Lei Wu, Qinyuan Zhao, Yemi Gao, Qi Gong, Fei Mao, Xiaokang Li, Hu Zhou, Jian Li, Haiyan ZhangAbstractIschemic stroke is a severe disorder resulting from acute cerebral thrombosis. Here we demonstrated that post-ischemic treatment with ciclopirox olamine (CPX), a potent antifungal clinical drug, alleviated brain infarction, neurological deficits and brain edema in a classic rat model of ischemic stroke. Single dose post-ischemic administration of CPX provided a long-lasting neur...
Source: Acta Pharmaceutica Sinica B - August 15, 2019 Category: Cancer & Oncology Source Type: research

Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer
Conclusions Receipts of CSFs and ESAs were significantly associated with an increased risk of VTE in women with breast cancer. Use of ESAs was significantly associated with substantially increased risks of MDS. These findings support those of previous studies.
Source: Cancer Causes and Control - April 7, 2016 Category: Cancer & Oncology Source Type: research

Therapeutic effects of umbilical cord blood plasma in a rat model of acute ischemic stroke.
This study provides valuable insights into the development of a safe, effective, and cell-free strategy for the treatment of ischemic brain damage and a much-needed alternative for patients who are ineligible for thrombolytic therapy. PMID: 27816964 [PubMed - as supplied by publisher]
Source: Oncotarget - November 8, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Deep learning-based classification of DSA image sequences of patients with acute ischemic stroke
CONCLUSION: Our deep learning-based approach to thrombus identification in DSA sequences yielded high accuracy on our single-center test data set. External validation is now required to investigate the generalizability of our method. As demonstrated, using this new approach may help reduce the incident risk of overlooking thrombi during thrombectomy in the future.PMID:35604489 | DOI:10.1007/s11548-022-02654-8
Source: Cancer Control - May 23, 2022 Category: Cancer & Oncology Authors: Benjamin J Mittmann Michael Braun Frank Runck Bernd Schmitz Thuy N Tran Amine Yamlahi Lena Maier-Hein Alfred M Franz Source Type: research

Cn-14 * retrospective analysis of ischemic cerebral strokes in patients diagnosed with a glioblastoma during the course of a bevacizumab treatment
Bevacizumab is an anti-vascular endothelial growth factor approved in the treatment of recurrent glioblastoma. It prolongs progression-free survival, improes radiologic response and contributes to reduce the dose of dexamethasone required to control peritumoral edema. Arterial and venous thromboembolic events represent significant toxicities related to the use of angiogenesis inhibitors. Various mechanisms could be implicated in bevacizumab-related strokes, as cardioembolic, lacunar stroke related to hypertension, deep venous thrombosis passing through a patent foramen ovale, pro-coagulant effect of the underlying glioblas...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Maurice, C., Mason, W. P. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research

Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
Authors: Thériault P, Le Béhot A, ElAli A, Rivest S Abstract Stroke is associated with neuroinflammation, neuronal loss and blood-brain barrier (BBB) breakdown. Thus far, recombinant tissue-type plasminogen activator (rtPA), the only approved treatment for acute ischemic stroke, increases the risk of intracerebral hemorrhage and is poorly efficient in disaggregating platelet-rich thrombi. Therefore, the development of safer and more efficient therapies is highly awaited. Encouraging neuroprotective effects were reported in mouse models of ischemic stroke following administration of erythropoietin (EPO). However, ...
Source: Oncotarget - June 2, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.
CONCLUSIONS: The economic burden of adverse events is relevant to programs and policies from clinic to government, and that burden merits consideration in the risks and benefits of adt. PMID: 24940106 [PubMed]
Source: Current Oncology - November 19, 2014 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
CONCLUSIONS: Among Asians, immune checkpoint inhibitors were associated with an increased risk of major adverse cardiovascular events, particularly ischemic stroke and pulmonary embolism.PMID:36208180 | DOI:10.1093/jjco/hyac150
Source: Clinical Lung Cancer - October 8, 2022 Category: Cancer & Oncology Authors: Cho-Han Chiang Cho-Hung Chiang Kevin Sheng-Kai Ma Yuan Ping Hsia Yu-Wen Lee Han-Ru Wu Cho-Hsien Chiang Chun-Yu Peng James Cheng-Chung Wei Her-Shyong Shiah Cheng-Ming Peng Tomas G Neilan Source Type: research

Cn-15 * adverse effects of bevacizumab in brain tumor patients
CONCLUSION: The range of toxicities was similar to other reports. Interestingly, hypertension was the most common adverse effect and was often not treated. The high incidence of lymphocytopenia may have implications for combination with immunotherapies. These findings underscore the need to develop predictive models to identify patients at high risk for serious treatment-related toxicities.
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Pawar, T., Ladha, H., Mandel, J., Gilbert, M., O'Brien, B., Hamza, M., Armstrong, T. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.
Conclusion: In ROCKET AF, a history of cancer was associated with a higher risk of bleeding and non-cardiovascular death, but not ischemic events. The relative efficacy and safety of rivaroxaban compared with warfarin were not significantly different in patients with and without a history of cancer. The results of this study are exploratory and should be taken in context of the study population, which may not be generalizable to those with advanced malignancy. Further investigation is needed to understand optimal anticoagulation strategies in patients with AF and cancer. PMID: 30219887 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - September 14, 2018 Category: Cancer & Oncology Authors: Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C Tags: Eur Heart J Qual Care Clin Outcomes Source Type: research

Incidence rates of cardiovascular outcomes in a community ‐based population of cancer patients
ConclusionsIn a population of patients with cancer not exposed to TKIs, cardiovascular risk factors and outcomes are very common, regardless of cancer type. These data can inform the evaluation of potential excess cardiovascular risks from new interventions.
Source: Cancer Medicine - October 29, 2019 Category: Cancer & Oncology Authors: Rajeev Masson, Lina Titievsky, Douglas A. Corley, Wei Zhao, Alfredo R. Lopez, Jennifer Schneider, Jonathan G. Zaroff Tags: ORIGINAL RESEARCH Source Type: research

Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
Curr Oncol. 2022 Aug 24;29(9):6077-6090. doi: 10.3390/curroncol29090478.ABSTRACTArterial thromboembolism has been associated with cancer or its treatment. Unlike venous thromboembolism, the incidence and risk factors have not been extensively studied. Here, we investigated the incidence of arterial thromboembolic events (ATEs) in an institutional series of advanced urinary tract cancer (aUTC) treated with cytotoxic chemotherapy. The ATE definition included peripheral arterial embolism/thrombosis, ischemic stroke and coronary events. A total of 354 aUTC patients were analyzed. Most patients (95.2%) received platinum-based c...
Source: Current Oncology - September 22, 2022 Category: Cancer & Oncology Authors: Aristotelis Bamias Kimon Tzannis Roubini Zakopoulou Minas Sakellakis John Dimitriadis Alkistis Papatheodoridi Loukianos Rallidis Panagiotis Halvatsiotis Anna Tsiara Maria Kaparelou Efthymios Kostouros Despina Barbarousi Konstantinos Koutsoukos Evangelos F Source Type: research